Abstract
There has been a significant reduction in the number of COVID cases world-wide since the pandemic peaked in 2022. However, new strains have developed in the two years following the peak that are significantly different genetically from their predecessors. This, combined with public apathy concerning vaccination and other preventative measures, has led to periodic outbreaks. The problem has been particularly troublesome in the U.S. So, what options are available to an individual who has developed a breakthrough infection, or has become COVID-19 positive due to negligence? This publication covers the mechanisms and side effects of COVID antiviral and anti-inflammatory drugs, interleukins, interferons, and monoclonal antibodies. The chemistry of these diverse therapeutic agents is complex, but their pharmacology, biochemistry, and even their molecular structures, are often related. These relationships will be explained, and the associated terminology demystified.